---
title: "Esperion’s Market Challenges: Sell Rating Due to Limited Impact of Bempedoic Acid and Mixed Feedback on Combination Strategy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265528988.md"
description: "Analyst Jason Zemansky from Bank of America Securities has maintained a Sell rating on Esperion, raising the price target to $1.72 from $1.60. The rating reflects concerns over the limited impact of bempedoic acid (BA) and mixed feedback on its combination strategy with generic statins. Key opinion leaders suggest BA may only have a niche role in the market, overshadowed by next-generation treatments. Additionally, practical concerns about the triple fixed-dose combination and patient resistance to multiple pills contribute to the Underperform rating."
datetime: "2025-11-12T12:45:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265528988.md)
  - [en](https://longbridge.com/en/news/265528988.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265528988.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/265528988.md) | [繁體中文](https://longbridge.com/zh-HK/news/265528988.md)


# Esperion’s Market Challenges: Sell Rating Due to Limited Impact of Bempedoic Acid and Mixed Feedback on Combination Strategy

Analyst Jason Zemansky from Bank of America Securities maintained a Sell rating on Esperion and increased the price target to $1.72 from $1.60.

### Meet Your ETF AI Analyst

-   Discover how TipRanks' _ETF_ AI Analyst can help you make smarter investment decisions
-   Explore ETFs TipRanks' users love and see what insights the **_ETF_ AI Analyst** reveals about the ones you follow.

Jason Zemansky has given his Sell rating due to a combination of factors surrounding Esperion’s current market position and product offerings. Despite efforts to highlight the potential of bempedoic acid (BA) during a recent presentation, the feedback from key opinion leaders (KOLs) was largely non-committal, suggesting that BA may only serve a niche role in the rapidly expanding competitive landscape. This is compounded by the presence of next-generation lipid-lowering treatments, such as PCSK9 inhibitors, which overshadow BA’s impact on lowering LDL-c levels.  
Furthermore, the prescriber feedback on Esperion’s triple fixed-dose combination (FDC) strategy was mixed. Concerns were raised about the practicality and necessity of combining BA with generic statins like atorvastatin and rosuvastatin, especially given the lack of synergistic LDL-c lowering effects. Additionally, psychological barriers to taking multiple pills were acknowledged, but the focus on ‘statin intolerance’ suggests that patients may resist this approach. These factors contribute to the maintained Underperform rating and a price objective of $1.72.

### Related Stocks

- [Esperion Therapeutics, Inc. (ESPR.US)](https://longbridge.com/en/quote/ESPR.US.md)

## Related News & Research

- [Esperion Completes Corstasis Acquisition, Expands Cardiovascular Portfolio](https://longbridge.com/en/news/281578871.md)
- [Esperion Insiders Quietly Cash Out as Top Executives Trim Their Stakes](https://longbridge.com/en/news/279718023.md)
- [The 4 Questions Investors Should Ask Before Buying Any ETF](https://longbridge.com/en/news/281549873.md)
- [Insig AI Plans Growth Drive and Eyes Nasdaq Dual Listing](https://longbridge.com/en/news/281311983.md)
- [What Happens Next After the QQQ ETF’s 3% Single-Day Move? Here’s What History Tells Us.](https://longbridge.com/en/news/281552388.md)